NCT02716246Phase 2, phase 3Recruiting

Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH

Study sponsor: Ultragenyx Pharmaceutical Inc · RARE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-03Estimated
Enrollment · participants36Estimated
Source updated2026-09-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Jul 2027. After: Mar 2029.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview